CMRX - キメリックス （Chimerix Inc.） キメリックス

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics. The rewards for bringing such products to market are significant. But biotech growth stocks also generally carry much higher risk than the average stock. Additionally, companies in the biotech industry face regulatory approval processes and intellectual property disputes that can result in significant near-term volatility. Nevertheless, the potential for substantial returns makes biotech stocks perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success. Let’s take a look at seven companies that I think fit that profile. ITOS iTeos Therapeutics $17.30 VIR Vir Biotechnology $22.84 BEAM Beam Therapeutics $39.10 KNSA Kiniksa Pharmaceuticals $12.28 DVAX Dynavax Technologies $10.44 CMRX Chimerix $1.63 APVO Aptevo Therapeutics $2.15 iTeos Therapeutics (ITOS) Source: motorolka / Shutterstock.com Stocks like iTeos Therapeutics (NASDAQ: ITOS ) are the kind of equity biotech investors ought to be looking for.

Chimerix, Inc. (NASDAQ:NASDAQ:CMRX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ETCompany ParticipantsMichelle LaSpaluto - Vice President-Strategic Planning and Investor…

DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Chimerix Inc. (CMRX) on Thursday reported a loss of $21 million in…

Chimerix press release (CMRX): Q4 GAAP EPS of -$0.24 in-line.Revenue of $0.8M (+1500.0% Y/Y) beats by $0.22M.“As we look to 2023, we are making tremendous progress and continuing…

- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study –

Chimerix Inc. has been awarded a contract by Canada worth up to $32.9 million for its smallpox drug likely to be used to treat monkeypox as it spreads across the world.

Chimerix Inc. has been awarded a contract by Canada worth up to $32.9 million for its smallpox drug likely to be used to treat monkeypox as it spreads across the world.

The contract, awarded by the Public Health Agency of Canada, comes a day after Chimerix announced an order worth $9.3-million for the smallpox drug, Tembexa

The shares of Chimerix (CMRX) rose on Friday after the company announced that Public Health Agency of Canada awarded it a contract to deliver up to $25.3M of Tembexa (brincidofovir),…

Chimerix Inc said on Friday it had been awarded a contract worth up to $25.3 million by Canada for its smallpox drug, likely to used to treat monkeypox as the viral infection spreads across the world.

Once a problem confined to just one continent, Monkeypox is spreading and threatens to become a global issue. Since the United Kingdom first reported a confirmed Monkeypox case on May 7, many more cases have been reported in countries where the virus hasn’t been originally known to be present. Nearly 800 cases have been detected so far, and investors are rightfully researching Monkeypox stocks to buy to position themselves for a potential upside during the second quarter of 2022. According to the World Health Organization (WHO), Monkeypox is a rare viral disease similar to smallpox but considered clinically less severe. It has been endemic in West Africa and Central Africa. Since it’s a viral disease, vaccination is the best front-line defense. It is widely believed that Smallpox vaccines are adequate for Monkeypox immunity. Unlike the Covid-19 scenario, when the world was vastly unprepared for a coronavirus outbreak, vaccines are already available for every American citizen should there be a Smallpox outbreak.

Chimerix Inc. (NASDAQ:CMRX) has a beta value of 1.34 and has seen 2.85 million shares traded in the last trading session. The company, currently valued at $158.30M, closed the last trade at $1.87 per share which meant it gained $0.09 on the day or 5.06% during that session. The CMRX stock price is -375.4% off … Chimerix Inc. (CMRX) Shares Are Down -70.92% YTD Read More »

Bluebird Bio (BLUE), Clovis Oncology (CLVS) and Chimerix (CMRX) are trading lower in the morning hours Thursday after Truist said that the three biotechs are at the risk of running out…

DURHAM, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 3:30 p.m. in New York City.

Futures Jump After Biden Says Trump''s China Tariffs Under Consideration US stock futures advanced for a second day after staging a furious rally late on Friday having slumped into a bear market just hours earlier, after President Joe Biden said China tariffs imposed by the Trump administration were under consideration, although concerns about hawkish central banks and record Covid cases in Beijing continued to weigh on the sentiment. Contracts on the S&P 500 were up 1% by 7:15 a.m. in New York, trimming earlier gains of as much as 1.4% following remarks from Christine Lagarde that the European Central Bank is likely to start raising interest rates in July and exit sub-zero territory by the end of September which sent the euro sharply higher and hit the USD. Meanwhile, Beijing and Tianjin continue to ramp up Covid restrictions as cases climbed. Nasdaq futures also jumped, rising 1.1%. Europe rose 0.6% while Asian stocks closed mostly in the green, with Nikkei +1% and Hang Seng -1.2%. The dollar and Treasuries retreated, while bitcoin jumped to $30,500 as the crypto rout appears over.